Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01298999 · ClinicalTrials.gov registry record · Phase 2
Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
NCT01298999 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 27 participants.
The verdict
NCT01298999, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.
Interventions
- DRUG Placebo
- DRUG YF476
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-06 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01298999
The ClinicalTrials.gov registry entry for NCT01298999 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01298999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01298999 about?
NCT01298999 is a clinical study titled "Trial of a Gastrin Receptor Antagonist in Barrett's Esophagus". The purpose of this study is to determine whether treatment with an experimental drug called YF476 in patients with Barrett's esophagus reduces the expression of tissue markers that are associated with an increased risk of developing esophageal cancer.
What is the current status of trial NCT01298999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2010-06. Estimated completion is 2017-12.
What interventions are being tested in trial NCT01298999?
The interventions under investigation include: Placebo (DRUG), YF476 (DRUG).
Who is sponsoring clinical trial NCT01298999?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.